Engineered acetylcholinesterase-loaded dissolvable microneedles mitigate dermal toxicity by targeting trichlorfon
Shuoqi Jiang1,2, Zi-Wei Zheng1, Qiuya Gu2
1Digital Industry Research Institute, Zhejiang Wanli University, No.8 South Qian Hu Road, Ningbo, Zhejiang, China.
None:
Trichlorfon (TCF), a widely used organophosphorus pesticide for crop protection, poses severe dermal toxicity risks as it readily penetrates the epidermal barrier and metabolizes into the more toxic dichlorvos (DDVP), triggering neurotoxicity, oxidative stress and inflammatory damage in exposed individuals. As a promising stoichiometric bioscavenger for pesticide detoxification, natural acetylcholinesterase (AChE) is still plagued by bottlenecks in thermal stability and transdermal delivery efficiency. To address these issues, this study employed a previously engineered high-activity and thermostable AChE variant (CpA-M5), evaluated its detoxification efficacy and mechanisms both in vitro and in vivo, and further developed a CpA-M5-loaded dissolvable microneedle system (CpA-M5-MN) for targeted dermal detoxification. In vitro assays demonstrated that CpA-M5 effectively restored endogenous AChE activity, scavenged ROS, reduced inflammation and alleviated apoptosis in TCF-exposed cells. Enzyme kinetics and molecular interaction analyses confirmed irreversible binding between CpA-M5 and TCF/DDVP, with DDVP showing higher binding affinity (K D = 9.23 × 10-6 M, Ki = 15.56 μM) and complex stability (K a = 2450.191 M-1, ΔG = -39.37 ± 1.48 kcal/mol). In vivo, the CpA-M5-loaded microneedle system achieved targeted transdermal delivery, effectively overcoming the limitations of low permeability and rapid degradation of free enzymes. Pathological and metabolomic analyses demonstrated that CpA-M5-MN reduced skin residual TCF/DDVP levels, restored local oxidative-inflammatory homeostasis, and regulated glutathione and amino acid metabolic pathways, thereby achieving synergistic detoxification and metabolic repair effects. Collectively, this work presents a promising targeted detoxification platform for pesticide-induced dermal injury, and provides new insights into the clinical translation of engineered enzyme-based bioscavengers.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Anthelminthic Agents
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

